Your GLP-1 Is Doing More to Your Brain Than You Think

The drug was working on his appetite. That much he knew. What he did not know was that it was also working on the part of his brain that makes you want your life.

GLP-1 drugs, the class that includes semaglutide, tirzepatide, and retatrutide, are understood by most people as appetite suppressants and blood sugar regulators. That framing is not wrong. But it is incomplete in a way that matters, because GLP-1 receptors are not just sitting in your gut and your pancreas. They are distributed throughout your brain, including deep inside the reward system, and when a drug activates those receptors at high enough concentrations, it changes how your brain generates desire for almost everything.

To understand why, you need the full chain first.

Your brain has a pathway called the mesolimbic dopamine system, which is the system responsible for motivating behavior. It starts in a region called the ventral tegmental area, or VTA, which is essentially the engine room for want. When the VTA fires, it releases dopamine into areas like the nucleus accumbens, and that dopamine signal is what creates what researchers call "wanting," which is the drive to pursue a reward before you have it. Not the pleasure of the reward itself. The anticipation, the seeking, the motivation to initiate. That is dopamine's actual job in this system.

Now here is where GLP-1 receptors enter the picture.

In a 2025 paper published in Science Advances, researchers mapped what happens when GLP-1 receptors in the VTA are activated. The VTA contains two types of neurons sitting right next to each other: dopamine neurons, which generate wanting, and GABA neurons, which function as a brake on those dopamine neurons. When GLP-1 receptors fire, they increase the activity of the GABA neurons. More GABA means more braking. More braking means the dopamine neurons fire less. The wanting signal gets turned down.

This is not theoretical. Researchers demonstrated it directly in the context of cocaine-seeking behavior, and the same mechanism applies to any reward-driven behavior the system governs, which includes food, alcohol, sex, and the general motivation to pursue things that matter to you.

Now here is the part that explains why people do not notice it happening.

A separate line of research has identified a distinction between two components of reward that most people treat as the same thing. "Wanting" is the dopamine-driven urge to seek a reward. "Liking" is the actual hedonic pleasure you experience when you get it. These are processed through different neural circuits, which means they can be altered independently.

A 2025 study found that semaglutide reduced reward-seeking behavior but did not reduce the hedonic response during the consummatory phase, meaning that sex still feels good when it happens, food still tastes good when you eat it, but the system that was supposed to be driving you toward those things in the first place has been quieted. Because nothing feels wrong in the moment, there is no signal that anything has changed. The absence of wanting does not feel like a symptom. It just feels like a quieter version of yourself.

And there may be a second mechanism running in parallel.

A 2026 clinical review proposed that GLP-1 agonists increase activity at something called the 5-HT2C receptor, which is the same serotonin receptor that produces sexual side effects in people taking SSRIs. SSRIs reduce libido through this pathway, and it is one of the most well-documented drug side effects in psychiatry. The review argues that GLP-1 drugs may be activating the same mechanism, which would mean there are potentially two separate systems both suppressing desire at the same time: one through dopamine reduction via VTA GABA activation, and one through serotonin receptor upregulation. The serotonin pathway in this context is theoretical and based on mechanistic inference rather than direct measurement in humans, but the structural logic is consistent with what clinicians are observing.

What makes this even harder to detect is that GLP-1 drugs also produce real improvements in wellbeing. Weight loss improves mood and self-image. Blood sugar stability reduces fatigue and brain fog. People feel objectively better in many dimensions. A 2026 review made the point explicitly: the positive effects of the drug compete with and mask the negative ones, so someone on semaglutide who has lost 30 pounds and feels less exhausted is not going to attribute their lower libido to the medication. They will attribute it to stress, or age, or their relationship, or the hundred other things people blame when something quiet and invisible shifts inside them.

The scope of the reward pathway effect has been confirmed in a different domain by a randomized controlled trial published in JAMA Psychiatry in 2025, where semaglutide was tested in 48 adults with alcohol use disorder. Participants taking once-weekly semaglutide showed significantly reduced alcohol consumption, fewer heavy drinking days, and lower craving scores compared to placebo. This is not an appetite effect. Alcohol has no caloric value that would trigger the GLP-1 satiety pathway. The only explanation is direct modulation of the mesolimbic reward system, and that confirmation matters because it shows the effect is not limited to food or sexual desire. It is a broad dampening of the wanting circuitry.

It is worth noting that not all studies show the same effect. A 2024 randomized double-blind trial in healthy men tested dulaglutide, a different GLP-1 agonist, over four weeks and found no measurable change in sexual function scores. That result does not contradict the mechanism but it illustrates that potency, CNS penetration, and duration all matter. Dulaglutide penetrates the blood-brain barrier less effectively than semaglutide, and four weeks at a lower CNS exposure may simply not be enough to produce a detectable signal in men who already had normal hormonal status and no other compounding factors.

For the practical question of reversibility: GLP-1 receptor agonists like semaglutide have a half-life of approximately one week, so after stopping, the drug clears within a few weeks and receptor signaling returns to baseline. The effect is not permanent structural change. It is a pharmacological state that exists while the drug is present and resolves when it is not.

What that means practically is this: if you are on one of these drugs and you have noticed that you have stopped pursuing things you used to want, whether that is sex, or hobbies, or ambitions, the first step is not changing your relationship or questioning your values. The first step is recognizing that you are running a compound that is actively interacting with the system your brain uses to generate motivation, and then deciding whether that tradeoff is one you want to make with full information.

Most people taking these drugs have never been told this is happening. The fact that it feels like nothing is what makes it so easy to miss.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness